Table 3.
Adverse reactions reported in ≥2% of linaclotide-treated (290 mcg) patients and at an incidence greater than in placebo group patients in the 2 phase 3, placebo-controlled trials (1 and 2) in irritable bowel syndrome with constipation1
| Adverse reactions | Linaclotide 290 mcg (n = 807) | Placebo (n = 798) |
| Diarrhea | 20% | 3% |
| Abdominal pain | 7% | 5% |
| Flatulence | 4% | 2% |
| Headache | 4% | 3% |
| Viral gastroenteritis | 3% | 1% |
| Abdominal distension | 2% | 1% |